ArticleScience China. Life sciences2022
Distinct durability of IgM/IgG antibody responses in COVID-19 patients with differing severity.
Abstract readLetterComment
In one paragraph
Article in Science China. Life sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Assessing the reporting quality of randomized controlled trials on COVID-19 vaccines: a systematic review.Human vaccines & immunotherapeutics · 2022Pooled it
- Differential immune profiles in elderly patients with non-severe versus severe SARS-CoV-2 omicron variant infection: dysregulation of antibody responses and B-cell subsets.Immunity & ageing : I & A · 2025Article
- Evaluation of oral health status and immunological parameters of hospitalized COVID-19 patients during acute and recovery phases: A randomized clinical trial.Journal of dental sciences · 2024Article
- Relatively rapid evolution rates of SARS-CoV-2 spike gene at the primary stage of massive vaccination.Biosafety and health · 2022Article
- Antibody neutralization to SARS-CoV-2 and variants after 1 year in Wuhan, China.Innovation (Cambridge (Mass.)) · 2022Article
- An Update on Protective Effectiveness of Immune Responses After Recovery From COVID-19.Frontiers in immunology · 2022Review
Corrections and comments
- Comment on
Authors and funding
29 authors.
Junyan Han *Beijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.
Ning Zhang *CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Center for Influenza Research and Early-warning (CASCIRE), CAS-TWAS Center of Excellence for Emerging Infectious Diseases (CEEID), Chinese Academy of Sciences, Beijing, 100101, China.
Danying Chen *Beijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.
Yuhuan Gong *CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Center for Influenza Research and Early-warning (CASCIRE), CAS-TWAS Center of Excellence for Emerging Infectious Diseases (CEEID), Chinese Academy of Sciences, Beijing, 100101, China.
Guoli Li *Beijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.
Yaxian KongBeijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.
Lin PuIntensive Care Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.
Chen ChenBeijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.
Jingyuan LiuIntensive Care Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.
Qi WangCenter of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.
Ju ZhangBeijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.
Xuesen ZhaoBeijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.
Juan DuBeijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.
Kai HanBeijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.
Chuan SongBeijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.
Linghang WangLaboratory of Infectious Diseases Center of Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.
Mingxi HuaBeijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.
Yu HaoBeijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.
Rui SongThe Infectious Disease Diagnostic, Therapeutic and Research Centers, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.
Yangzi SongClinical Center for HIV/AIDS, Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.
Fengting YuClinical Center for HIV/AIDS, Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.
Siyuan YangLaboratory of Infectious Diseases Center of Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.
Haofeng XiongIntensive Care Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.
Wei ZhangThe Infectious Disease Diagnostic, Therapeutic and Research Centers, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.
George F GaoCAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Center for Influenza Research and Early-warning (CASCIRE), CAS-TWAS Center of Excellence for Emerging Infectious Diseases (CEEID), Chinese Academy of Sciences, Beijing, 100101, China. gaof@im.ac.cn.
Fujie ZhangClinical Center for HIV/AIDS, Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China. treatment@chinaaids.cn.
Ang LiIntensive Care Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China. liang@ccmu.edu.cn.
Hui ZengBeijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China. zenghui@ccmu.edu.cn.
Yuhai BiCAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Center for Influenza Research and Early-warning (CASCIRE), CAS-TWAS Center of Excellence for Emerging Infectious Diseases (CEEID), Chinese Academy of Sciences, Beijing, 100101, China. beeyh@im.ac.cn.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
COVID-19Immunoglobulin GAntibodies, ViralAntibody FormationHumansImmunoglobulin MSARS-CoV-2Antibodies, ViralImmunoglobulin GImmunoglobulin M
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.